Last reviewed · How we verify
Ivermectin + colchicine
This combination uses ivermectin's antiparasitic and anti-inflammatory properties alongside colchicine's anti-inflammatory effects to reduce inflammation and parasitic burden.
This combination uses ivermectin's antiparasitic and anti-inflammatory properties alongside colchicine's anti-inflammatory effects to reduce inflammation and parasitic burden. Used for Parasitic infections with inflammatory complications, COVID-19 (investigational use in some regions).
At a glance
| Generic name | Ivermectin + colchicine |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Antiparasitic + anti-inflammatory combination |
| Target | Glutamate-gated chloride channels (ivermectin); tubulin/microtubules (colchicine) |
| Modality | Small molecule |
| Therapeutic area | Infectious disease / Immunology |
| Phase | FDA-approved |
Mechanism of action
Ivermectin binds to glutamate-gated chloride channels in parasites, causing paralysis and death, while also exhibiting immunomodulatory effects that suppress pro-inflammatory cytokines. Colchicine inhibits microtubule polymerization, reducing neutrophil migration and inflammatory mediator release. Together, they target both parasitic infection and excessive inflammatory responses.
Approved indications
- Parasitic infections with inflammatory complications
- COVID-19 (investigational use in some regions)
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea)
- Headache
- Dizziness
- Colchicine-related diarrhea and abdominal pain
- Myalgia
Key clinical trials
- Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial (NA)
- Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ivermectin + colchicine CI brief — competitive landscape report
- Ivermectin + colchicine updates RSS · CI watch RSS
- Ain Shams University portfolio CI